Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Suzhou Basecare Medical Corp. Ltd. Class H ( (HK:2170) ) has shared an update.
Suzhou Basecare Medical Corporation Limited has scheduled a board meeting for March 30, 2026, to review and approve the annual results of the company and its subsidiaries for the financial year ended December 31, 2025. The board will also consider the potential recommendation of a final dividend, a decision that could directly affect shareholder returns and signal management’s confidence in the company’s financial performance.
The outcome of this meeting will shape the timing and content of the forthcoming results announcement, which is closely watched by investors for insight into the company’s operational health. Any dividend recommendation, if approved, may influence the firm’s capital allocation profile and market perception, particularly within the Hong Kong investment community that tracks listed medical and healthcare-related issuers.
The most recent analyst rating on (HK:2170) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Suzhou Basecare Medical Corp. Ltd. Class H stock, see the HK:2170 Stock Forecast page.
More about Suzhou Basecare Medical Corp. Ltd. Class H
Suzhou Basecare Medical Corporation Limited is a PRC-incorporated medical company listed in Hong Kong under stock code 2170. The group operates through its subsidiaries in the healthcare sector, with a board comprising executive, non-executive, and independent non-executive directors overseeing its strategic and financial management.
Average Trading Volume: 173,377
Technical Sentiment Signal: Sell
Current Market Cap: HK$560.7M
Learn more about 2170 stock on TipRanks’ Stock Analysis page.